Dermapharm Holding SE

Total Valuation

Dermapharm Holding SE carries a market capitalization of 2.36B, placing it among publicly traded companies globally. Its enterprise value stands at 2.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Dermapharm Holding SE currently has 53.84M shares outstanding.

Valuation Ratios

Dermapharm Holding SE trades at a trailing price-to-earnings ratio of 15.66. The price-to-sales ratio is 1.93, and the price-to-book ratio stands at 3.67.

Enterprise Valuation

On an enterprise value basis, Dermapharm Holding SE trades at an EV/EBITDA multiple of 8.40 and an EV/FCF ratio of 5.49. The EV/Sales ratio of 1.71 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.40 provides insight into valuation relative to core operating earnings.

Financial Position

Dermapharm Holding SE maintains a current ratio of 2.00, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Dermapharm Holding SE posts a return on equity of 25.40 and a return on invested capital of 24.15.

Taxes

Over the trailing twelve months, Dermapharm Holding SE has paid 52.07M in income taxes, reflecting an effective tax rate of 26.65.

Stock Price Statistics

Dermapharm Holding SE's stock has gained approximately 20.55106% over the past 52 weeks. The 50-day moving average sits at 45.37, while the 200-day moving average is 41.01.

Income Statement

Over the trailing twelve months, Dermapharm Holding SE generated 1.17B in revenue and converted that into 144.21M in net income, yielding earnings per share of 2.67. EBITDA reached 238.19M, while operating income came in at 238.19M.

Balance Sheet

Total book value stands at 614.95M, with working capital of 389.81M providing operational flexibility.

Cash Flow

Dermapharm Holding SE produced 284.74M in operating cash flow over the past twelve months. After subtracting -43.89M in capital expenditures, free cash flow totaled 240.85M - equivalent to 4.49 per share.

Margins

Dermapharm Holding SE operates with a gross margin of 67.74, reflecting its pricing power and cost economics. The operating margin of 20.39 and net profit margin of 12.34 provide insight into operational efficiency.

Dividends & Yields

Scores

Dermapharm Holding SE posts an Altman Z-Score of 3.53, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.